RxDoctor Payments Data

Jennifer Jue, PA

Physician Assistant · New York, NYNPI 1568097533

Payments from drug & device makers

$2,994in general payments, 2019–2025

Across 52 payments — averaging $57.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Valencia Technologies Corporation$2K
  • Medtronic$313
  • Rochester Medical Corporation$302
  • Astellas Pharma US Inc$201
  • Coloplast$185
  • Axonics, Inc.$113
  • plus $260 from 6 others

What the payments were for

  • Travel & lodging$1,56052%
  • Food & beverage$1,36245%
  • Education$732%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Valencia Technologies Corporation2$1,620
Medtronic5$313
Rochester Medical Corporation21$302
Astellas Pharma US Inc5$201
Coloplast3$185
Axonics, Inc.5$113
Urogen Pharma, Inc.4$94
AbbVie2$50
Boston Scientific1$42
Endo Pharmaceuticals Inc.2$31
Immunitybio, Inc.1$22
Merck1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,994 in reported general payments places this provider in the 85th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$46,678
Medicare patients
108
Services billed
955

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron270$153,424
GemtesaVibegron174$104,208
Estradiol230$18,401
BotoxOnabotulinumtoxina14$9,974
Methenamine Hippurate157$8,813
Mirabegron ErMirabegron14$7,414
PremarinEstrogens, Conjugated17$7,057
Fosfomycin Tromethamine11$1,752
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst102$1,268
YuvafemEstradiol22$1,185
Solifenacin Succinate16$1,094
Tamsulosin Hcl39$475
Hydroxyzine Hcl14$240
Gabapentin11$238
Amitriptyline Hcl16$210

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$201$153,424270 claims
AbbVieBotox$50$9,97414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →